Precede Biosciences’ Post

Jennifer Herrera-Mullar, MGC, LCGC, discusses the takeaway points of one of Ambry’s poster presentations at #CGC2024. This summary explores two important aspects of gene-disease validity curation: how scoring methods have evolved over time and how GDV impacts the clinical utility of multi-gene panel testing. Watch the video to find out what trends they discovered. #genetictesting #hereditarycancer #variantclassification

It was an honor to be invited to present at the EMBO Inflammasome Workshop at Ludwig-Maximilians-Universität München in Munich. Our Chief Scientific Officer, Michael Crackower, presented our progress on the development of first-in-class caspase-4 inhibitors using our proprietary, biophysics-based and #machinelearning -enabled platform, ReSOLVE™. This is our first disclosure of our groundbreaking discovery of allosteric, selective, small-molecule caspase-4 inhibitors that are highly potent in vitro and in vivo and work via a previously undiscovered mechanism. The role of caspase-4 at the interface of bacterial components and the production of numerous cytokines makes this a highly compelling target for diseases of high unmet need like #InflammatoryBowelDisease, hidradenitis suppurative, and sepsis, where single cytokine inhibition has resulted in sub-optimal efficacy. Learn more about the power of our approach at https://www.ventustx.com/ and the event at https://lnkd.in/eGKQUFx7.

Want to hear about how our team discovered the novel molecular subtypes of papillary thyroid cancer identified by Thyroid GuidePx? Have a listen. #papillarythyroidcancer #thyroidcancer #precisiononcology #NGS #cancer

If you are thinking about getting study going this fall, let's talk! Here is a link to my calendar if you would like to find a time that works for you or DM me to book: https://lnkd.in/gBrqSbx7

Here’s our second abstract poster from the #SABCS2024: "Analytical Validity of the Digistain Test in the Face of Variable Fixation Times – A Study from Charing Cross Hospital". Tissue processing variations can impact #RNA integrity in PCR-based risk profiling tests, such as some #genomictests. To address this, we evaluated the robustness of the Digistain test across different fixation times. We’re proud to share that results from our molecular assay showed no statistical variability, confirming its reliability in clinical settings, positioning Digistain as a reliable tool for #breastcancer risk stratification in adjuvant therapy. Read the full abstract here: https://lnkd.in/es_tiUW2

NEW BLOG ALERT: The Best Managed Biobank is an Empty Biobank – A Fresh Approach to Specimen Procurement In a conference room several years ago, we heard a statement that truly resonated with us: “The best biobank is an empty biobank.” It was a striking concept, especially in a field that has traditionally valued massive volume over meaningful inventory. But that simple statement changed our thinking about how we procure and provide specimens, and how we wanted to do things differently at Reference Medicine. It pushed us to reflect on how specimen procurement has evolved—or in many ways, how it hasn’t. Read more about how we take a fresh approach to specimen procurement here. https://lnkd.in/eJ4-e-QQ #oncologyresearch #cancerresearch #medicaldiagnostics #innovation

Another advantage of ARCTis™ Human Tumor plates is the level of quality. By repeatedly producing the same thing my team knows exactly what to do and has gathered a ton of experience with it. For our productions there are SOPs in place that are followed step by step, checklists filled in, and so we ensure that each production is as good as the previous one. Of course, there is some biological variation that derives from the start material. However, by adhering strictly to the processes our input is negligible. In addition, we collaborate with external testing labs to guarantee that no contamination is present on the ARCTis™ plates nor on in the medium that comes with them. Plus, we run a quality control plate for each batch and check the aggregation behavior, growth and metabolic activity. In short, as long as a customer follows the instructions from our Quick Start Guide their results should be the same than ours. Have a look at the scans of the plates from a recent production for our Starter Pack. This is as good as it is technically possible. To give you a sizing idea, the well diameter is 1mm. #3dcellculture #microtissues #cancer_research #preclinical #invitro InSphero

🎥 Catch our recent video with Dr. Patrick Soon-Shiong of ImmunityBio, Inc. on the groundbreaking data related to #nogapendekin #alfa #inbakicept (#Anktiva) for #NMIBC presented at #AUA24. 📺 Watch Now:

Want to know more about cytokine and the challenges associated with their clinical application? Discover more as we discuss the use of cytokines in immunotherapy in this introductory video sponsored by Sino Biological, Inc.. >>> https://hubs.ly/Q02HcqK60

🚀 Exciting News: New Fibrosis Landing Page Launch!  We're thrilled to introduce our new resource on mechanobiology of Fibrosis – a promising tool for disease modeling and drug development. Existing methods and biomarkers often fall short of understanding the mechanical microenvironment of fibrotic tissues, leading to inconclusive preclinical results. But we're committed to overcoming these challenges! By focusing on mechanical measurements and quantifying microscale variations in stiffness and viscoelasticity, our platform helps identify the key mechanical biomarkers that drive fibrosis progression. Explore the future of fibrosis research today –  https://t.ly/mcviY - and access insightful Application Notes, White Papers & Case Studies to enhance your research. Get in touch: https://t.ly/8WzwB #Fibrosis #DrugDevelopment #DiseaseModeling #Biomarkers #ResearchInnovation #MechanicalMeasurements Optics11 Life